title: [Prevalence of anti-HAV antibodies and efficacy of pre-vaccine detection at institutions for mentally retarded of the city of Alicante].
abstract: OBJECTIVE
  The aim of this study was to investigate the prevalence and efficacy of the anti-HAV antibodies detection in institucions for mentally retarded people in the city of Alicante.
  
  
  METHODS
  Prevalence study.
  
  
  METHODS
  Two institucions for mentally retarded people in the city of Alicante.
  
  
  METHODS
  One hundred and seven residents and seventy seven in care of them.
  
  
  RESULTS
  We have investigated the anti-HAV antibodies prevalence by enzymeinmunoanalysis of microparticle test. The efficacy of the anti-HAV antibodies detection before the vaccination has been studied by calculating the threshold of prevalence with the following formula: unit cost of detection + (1 - X) x unit cost vaccination anti-HAV negative subjects = unit cost vaccination.
  
  
  RESULTS
  The global prevalence of anti-HAV antibodies was 56.5% (95% CI, 49-63.7). The prevalence of the residents was 55.1% (95% CI, 45.2-64.7) and 58.4% in care of them (95% CI, 46.6-69.5). Among the sociodemographic variables evaluated only the age was associated with the prevalence of anti-HAV antibodies (p < 0.001). The unit cost of prevaccination detection of anti-HAV antibodies was calculated as 998 pesetas and the unit cost of the vaccination as 3595, obtaining a prevalence anti-HAV threshold of 27.8%.
  
  
  CONCLUSIONS
  The prevalence of anti-HAV antibodies in this collective studied is similar to the prevalence of anti-HAV antibodies of the spaniard population. The direct vaccination without a previous marker study is recommended to people under the age of 31 in this population group.
authors.affiliation: Centro de Salud Pública, Hospital Universitario, Centro de Atención Primaria de San Juan, Alicante. francisco.martinezcampillo@sanidad.m400.gva.es
authors.forename: F
authors.initials: F
authors.lastname: Martínez-Campillo
authors.forename: M
authors.initials: M
authors.lastname: Terán
authors.forename: M
authors.initials: M
authors.lastname: Alvarez
authors.forename: M V
authors.initials: MV
authors.lastname: Rigo
authors.forename: J
authors.initials: J
authors.lastname: Roda
authors.forename: M
authors.initials: M
authors.lastname: Salinas
authors.forename: J M
authors.initials: JM
authors.lastname: García
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006506:Hepatitis A / Q000097:blood* / Q000453:epidemiology*; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies / Q000097:blood*; D006507:Hepatovirus / Q000276:immunology*; D006778:Hospitals, Psychiatric; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016036:Seroepidemiologic Studies; D013030:Spain; D014761:Viral Hepatitis Vaccines
chemical_list: D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D014761:Viral Hepatitis Vaccines
vernacular_title: Prevalencia de anticuerpos anti-VHA y eficiencia de la detección prevacunal en instituciones de deficientes psíquicos de la ciudad de Alicante.